Viatris Inc
In the published model solve dated 2026-Q2, anchored at $17.64, Viatris Inc (VTRS) is priced for today's economics sustained for ~9.1 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed August 7, 2026 from SEC EDGAR filings.
• Reported profit is mostly an accounting artifact: roughly 2.36 billion dollars of purchase-accounting amortisation ran through the income statement in the year to March 2026, which is why operating profit of 139.4 million dollars sits alongside guided 2026 operating cash generation of 1.9 to 2.1 billion dollars [Source: Q2 2026 earnings release, August 6, 2026]. • The clearest near-term risk is supply rather than demand: the Nashik oral solid dose plant drew FDA Form 483 observations in May 20
Is VTRS overvalued? See what's priced in →
986 institutional managers reported holding VTRS in 13F filings for the quarter ended 2026-03-31. Together they hold about 84% of the company; the top 10 hold 48%. 110 opened new positions that quarter. Held by Vanguard Group, BlackRock, T. Rowe Price, among others. On the short side, 45.1M shares were sold short as of the 2026-06-15 count, about 4% of shares outstanding (5.1 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
VTRS has cut its share count 4.4% over the past five years, spending $1.01B on repurchases. It pays no dividend. Cash returned over the past three years: $757.20M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at VTRS over the trailing three years: 2023: 1 buy totaling $0k; 2025: 4 buys totaling $761k. 21 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
VTRS's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-08 | +5.3% | -13.7% |
| 2023-11-09 | +0.1% | +33.2% |
| 2024-02-29 | -6.5% | -6.2% |
| 2024-05-10 | -5.5% | +0.7% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
VTRS's latest 8-K filings: 2026-08-06 (items 2.02, 8.01, 9.01); 2026-07-01 (items 1.01, 2.03, 9.01); 2026-06-18 (items 1.01, 2.03, 9.01); 2026-06-15 (items 8.01, 9.01); 2026-05-15 (items 5.07).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: August 7, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.